Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQB3454 + serplulimab + docetaxel in previously treated advanced non-small cell lung cancer
ChiCTR2400086196Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQB3454, serplulimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective response rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
TQB3454serplulimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086196.